Hunting For Viruses With Andy Kaufman & Sam Bailey.

⁣"We don't call them covid-positive PCRs any more. We call them genomes of Zurich."

Anthony Fauci's wife decided she wants a piece of the action also now; so, she's writing a new book that should be coming out next month. ... It's called, "I Married a Vax Murderer."

great interview, thanks for adding to the list

⁣Please please sign the petition for the sake of our sons and daughters.
We need 100,000 names.
⁣Petition Do not vaccinate children against COVID-19 until Phase 3 trials are complete.
⁣⁣https://petition.parliament.uk/petitions/586017

Reply from the Government.
⁣The Government has responded to the petition you signed – “Do not vaccinate children against COVID-19 until Phase 3 trials are complete”.

Government responded:


The Government will continue to evaluate evidence and
assess expert opinion before making a decision on routinely vaccinating
children under 18 years old.



No decision has been made by the Government regarding the
routine inclusion of children under 18 years within the COVID-19
vaccination programme at a population level. The Government will be
guided by the advice of the UK’s independent medicines regulator, the
Medicines and Healthcare products Regulatory Agency (MHRA), whose role
is to ensure medicines, devices and vaccines work effectively and are
safe for use.

MHRA have now authorised the use of Pfizer/ BioNTech vaccine in
children aged 12-15. This follows a rigorous review of the safety,
quality and effectiveness of the vaccine in this age group by the MHRA
and the Government’s independent advisory body, the Commission on Human
Medicines (CHM). Over 2,000 children aged 12-15 years were studied as
part of the randomised, placebo-controlled clinical trials. There were
no cases of COVID-19 from 7 days after the second dose in the vaccinated
group, compared with 16 cases in the placebo group. In addition, data
on neutralising antibodies showed the vaccine working at the same level
as seen in adults aged 16-25 years. No new side effects were identified
and the safety data in children was comparable with that seen in young
adults. As in young adults, the majority of adverse events were mild to
moderate and relating to reactogenicity, such as a sore arm or
tiredness.

Any vaccine must first go through the usual rigorous testing and
development process and meet strict standards of safety, quality and
effectiveness before it can be deployed. There are extensive checks and
balances at every stage of the development of a vaccine. The data looked
at includes all the results from laboratory studies, clinical trials,
manufacturing and quality controls and testing of the product. The
public should be very confident that all tests are completed to the very
highest standards.

For all vaccines authorised for supply in the UK, including COVID-19
vaccines, each candidate is assessed by teams of scientists and
clinicians on a case by case basis and is only authorised once it has
met robust standards of effectiveness, safety and quality set by MHRA.

Once a vaccine is approved for use in the UK, the Joint Committee on
Vaccination and Immunisation (JCVI), an independent body made up of
scientific and clinical experts, will provide advice to the Government
on which safe, effective vaccines to use, and advise on prioritisation
at a population level. The committee’s membership is made up of public
health and scientific experts who have considered and continue to
consider the impact of COVID-19 and population prioritisation as new
data emerges.

Now that the Pfizer/BioNTech vaccine has been authorised for use in
children aged 12-15 in the UK, we will be guided by the advice of
experts, including the JCVI, on any potential deployment of COVID-19
vaccination in children under the age of 18.

No decisions have been made by the Government on the routine COVID-19
vaccination of children. In line with the advice of the JCVI for Phase
One of the vaccination programme, children/young adults aged 16-18 could
be offered a vaccine if they have an underlying condition that put them
at increased risk from COVID-19. However, the JCVI currently advises
that children under 16 years of age, even if they are clinically
extremely vulnerable (CEV), are at low risk of serious morbidity and
mortality and given the absence of safety and efficacy data on COVID-19
vaccines, are not currently recommended for routine COVID-19
vaccination.

Following infection, almost all children will also have asymptomatic
infection or mild disease. Therefore, only children under 16 who are at
very high risk of exposure and serious outcomes, such as those with
severe neuro-disabilities that require residential care, may be
considered for a COVID-19 vaccination. This is given the very high risk
of exposure to infection and outbreaks in residential settings.
Decisions to vaccinate such children should be made on a case by case
basis, with consultation taking place between clinicians, parents/carers
and children. The MHRA updated its authorisation guidance in relation
to the currently approved vaccines in February to allow this approach.

The JCVI continues to look at the emerging evidence on COVID-19, and
will offer further advice to the Government if and when evidence is
found that routinely vaccinating children under 18 years old would
further reduce overall mortality, morbidity and hospitalisation which is
the overarching objective of the COVID-19 vaccination programme.

Department for Health and Social Care


Click this link to view the response online:

https://petition.parliament.uk..../petitions/586017?re

The Petitions Committee will take a look at this petition and its
response. They can press the government for action and gather evidence.
If this petition reaches 100,000 signatures, the Committee will consider
it for a debate.

The Committee is made up of 11 MPs, from political parties in
government and in opposition. It is entirely independent of the
Government. Find out more about the Committee: https://petition.parliament.uk..../help#petitions-comm

Thanks,

The Petitions team

UK Government and Parliament